Cenexi | Cenexi Hérouville Saint Clair

This additional site acquired in 2017 from MSD, allowed Cenexi to significantly increase its syringe, vial, and ampoule filling capacity. This site also manufactures creams, ointments, lotions, drops, and syrups to treat allergies, inflammatory and infectious diseases, and cancers. The site has increased its capacity in sterile products in all forms, in particular, by introducing the manufacture of an ophthalmic gel. In December 2021, Hérouville reached a major milestone in its development by obtaining FDA accreditation for the production of a sterile injectable product, aseptically packaged in vials for the USA. It had already obtained accreditations from the Brazilian, French, and Russian health authorities. Finally, the ANSM recently authorized the site to manufacture and certify biological products (immunological and biotechnology). The physicochemistry and microbiology control laboratories also allow on-site analyzes (packaging materials, raw materials, semi-finished products, and finished products).